Bronchoprotective effects of single doses of salmeterol combined with montelukast in thermally induced bronchospasm

Chest

Volumn 127, Issue 5, 2005, Pages 1572-1578

  Coreno, Albert ^b   Skowronski, Mary ^b   West, Erin ^b   El Ekiaby, Amr ^b   McFadden Jr , E R ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

^b NONE

Author keywords

Airway hyperresponsiveness; Bronchospasm; Montelukast; Prophylaxis; Salmeterol; Thermally induced asthma

Indexed keywords

MONTELUKAST; SALMETEROL; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; BRONCHODILATING AGENT; DRUG DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE; SALBUTAMOL;

ALLERGIC ASTHMA; ARTICLE; BRONCHODILATATION; BRONCHOSPASM; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXERCISE; FORCED EXPIRATORY VOLUME; HUMAN; HYPERVENTILATION; MONOTHERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; THERMAL EXPOSURE; ADULT; DRUG COMBINATION; DYSPHAGIA; FEMALE; MALE; MIDDLE AGED; TEMPERATURE;

ACETATES; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; BRONCHODILATOR AGENTS; DEGLUTITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; MIDDLE AGED; QUINOLINES; TEMPERATURE;

EID: 19844361924     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.127.5.1572     Document Type: Article

References (33)

1. Holgate ST. The cellular and mediator basis of asthma in relation to natural history. Lancet 1997; 350(suppl) 115s-119s
2. McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med 1994; 330:1362-1367
3. 2-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma. J Allergy Clin Immunol 2000; 106:500-506
4. 4-receptor antagonist cinalukast. J Allergy Clin Immunol 1997; 99:210-215
5. Bronsky EA, Kemp JP, Zhang J, et al. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997; 62:556-561
6. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997; 52:1030-1035
7. Leff JA, Busse WW, Pearlman D, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147-152
8. Kemp JP, Dockhorn RJ, Busse WW, et al. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med 1994; 150:1612-1615
9. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med 1998; 339:141-146
10. Newnham DM, Ingram CG, Earnshaw J, et al. Salmeterol provides prolonged protection against exercise-induced bronchoconstriction in a majority of patients with mild, stable asthma. Respir Med 1993; 87:439-444
11. Vilaran C, O'Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. J Allergy Clin Immunol 1999; 104:547-553
12. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: a randomized, double-blind trial. Ann Intern Med 2000; 132:97-104
13. Kraft M, Wenzel S, Bettinger C, et al. The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma. Chest 1997; 111:1249-1254
14. Weersink EJM, Aalbers R, Koeter GH, et al. Partial inhibition of the early and late asthmatic response by a single dose of salmeterol. Am J Respir Crit Care Med 1994; 50:1262-1267
15. Gilbert IA, McFadden ER Jr. Airway cooling and rewarming: the second reaction sequence in exercise-induced asthma. J Clin Invest 1992; 90:699-704
16. Onorato DJ, Demirozu MC, Breitenbucher A, et al. Airway mucosal blood flow in humans: response to adrenergic agonists. Am J Respir Crit Care Med 1994; 149:1132-1137
17. Pizzichini E, Leff JA, Reiss TF, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir J 1999; 14:12-18
18. National Asthma Education and Prevention Program. Expert panel report II: guidelines for the diagnosis and management of asthma. Bethesda, MD: National Institutes of Health; April 1997; NIH Publication No. 97-4051
19. Deal EC Jr, McFadden ER Jr, Ingram RH Jr, et al. Airway responsiveness to cold air and hyperpnea in normal subjects and in those with hay fever and asthma. Am Rev Respir Dis 1980; 121:621-628
20. World Medical Association. World Medical Association declaration of Helsinski: recommendations guiding a physicians in biomedical research involving human subjects. JAMA 1997; 277:925-926
21. Gilbert IA, Fouke JM, McFadden ER Jr. Intra-airway thermodynamics during exercise and hyperventilation in asthmatics. J Appl Physiol 1988; 64:2167-174
22. Strauss RH, McFadden ER Jr, Ingram RH Jr, et al. Enhancement of exercise-induced asthma by cold air. N Engl J Med 1977; 297:743-747
23. Anderson S, Seale JP, Ferris L, et al. An evaluation of pharmacotherapy for exercise-induced asthma. J Allergy Clin Immunol 1979; 64:612-624
24. 4-receptor antagonist. N Engl J Med 1990; 323:1736-1739
25. Makker HK, Lau LC, Thomson HW, et al. The protective effect of inhaled leukotriene D4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993; 147:1413-1418
26. Israel E, Dermarkarian R, Rosenberg M, et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323:1740-1744
27. Dempsey OJ, Wilson AM, Sims EJ, et al. Additive bronchoprotective and bronchodilator effects with single doses of salmeterol and montelukast in asthmatic patients receiving inhaled corticosteroids. Chest 2000; 117:950-953
28. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337:1062-1063
29. Pliss LB, Ingenito P, Ingram RH et al. Assessment of bronchoalveolar cell and mediator response to isocapnic hyperpnea in asthma. Am Rev Respir Dis 1990; 142:73-78
30. Jarjour NN, Calhoun WJ. Exercise-induced asthma is not associated with mast cell activation or airway inflammation. J Allergy Clin Immunol 1992;89:60-68
31. 4 excretion in exercise-induced asthma. J Appl Physiol 1992; 73:743-748
32. Kemp JP, Dockhorn RJ, Busse WW, et al. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med 1994; 150:1612-1615
33. Ramage L, Lipworth BJ, Ingram CG, et al. Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol. Respir Med 1994; 88:363-368